|
US5538983A
(en)
|
1990-05-16 |
1996-07-23 |
The Rockefeller University |
Method of treating amyloidosis by modulation of calcium
|
|
HUT66324A
(en)
|
1991-07-29 |
1994-11-28 |
Warner Lambert Co |
Quinazoline derivatives as acetylcholinesterase inhibitors and pharmaceutical compositions containing them
|
|
IT1255179B
(it)
|
1992-06-26 |
1995-10-20 |
Enzo Cereda |
Azaciclo e azabiciclo alchiliden idrossilamine
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2992677B2
(ja)
|
1995-06-05 |
1999-12-20 |
武田薬品工業株式会社 |
骨形成促進医薬組成物
|
|
AU5716898A
(en)
|
1997-01-08 |
1998-08-03 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
US6569897B1
(en)
|
1998-01-16 |
2003-05-27 |
Purdue Research Foundation |
Alkenyldiarylmethane non-nucleoside HIV-1 reverse transcriptase inhibitors
|
|
DE69934093T2
(de)
|
1998-01-27 |
2007-06-21 |
Aventis Pharmaceuticals Inc. |
SUBSTITUIERTE OXOAZAHETEROCYCLYL FAKTOR Xa HEMMER
|
|
JP2003529531A
(ja)
|
1998-11-25 |
2003-10-07 |
アヴェンティス ファーマシューティカルズ インコーポレイテッド |
置換オキソアザへテロシクリルＸａ因子阻害剤
|
|
HK1054227A1
(zh)
|
1999-07-28 |
2003-11-21 |
阿温蒂斯药物制品公司 |
取代的氧代氮杂杂环基化合物
|
|
JP2001131173A
(ja)
|
1999-08-23 |
2001-05-15 |
Kyorin Pharmaceut Co Ltd |
二環式複素環誘導体
|
|
JP2005231995A
(ja)
|
1999-12-22 |
2005-09-02 |
Meiji Seika Kaisha Ltd |
オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
CA2411386A1
(en)
|
2000-06-30 |
2002-01-10 |
Eli Lilly And Company |
Combination therapy for treatment of psychoses
|
|
JP2004532200A
(ja)
|
2001-03-15 |
2004-10-21 |
サエジス ファーマシューティカルズ， インコーポレイテッド |
全身性ストレスの後に認識機能を回復するための方法
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20030004913A1
(en)
|
2001-07-02 |
2003-01-02 |
Koninklijke Philips Electronics N.V. |
Vision-based method and apparatus for detecting an event requiring assistance or documentation
|
|
JP4620349B2
(ja)
|
2001-11-26 |
2011-01-26 |
コーテックス ファーマシューティカルズ， インコーポレイテッド |
グルタメートシナプシス応答向上のためのカルボニルベンゾキサジン化合物
|
|
US20040044023A1
(en)
|
2002-08-30 |
2004-03-04 |
Marc Cantillon |
Compositions and methods for treating or preventing memory impairment
|
|
US20060233843A1
(en)
|
2003-02-19 |
2006-10-19 |
Conn P J |
Treatment of psychosis with a muscarinic m1 receptor ectopic activator
|
|
BRPI0409523A
(pt)
|
2003-03-28 |
2006-04-18 |
Acadia Pharm Inc |
método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
|
|
US20040266659A1
(en)
|
2003-06-27 |
2004-12-30 |
Stephen LaBerge |
Substances that enhance recall and lucidity during dreaming
|
|
GB0504019D0
(en)
|
2005-02-26 |
2005-04-06 |
Astrazeneca Ab |
Amide derivatives
|
|
EP1877093A2
(en)
|
2005-04-15 |
2008-01-16 |
Board of Trustees of Michigan State University |
Ascorbate binding peptides
|
|
GB0516570D0
(en)
|
2005-08-12 |
2005-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
WO2007044937A2
(en)
|
2005-10-13 |
2007-04-19 |
President And Fellows Of Harvard College |
Compositions and methods to modulate memory
|
|
ES2612377T3
(es)
|
2005-12-21 |
2017-05-16 |
Janssen Pharmaceutica N.V. |
Triazolopiridazinas como moduladores de tirosina cinasas
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US7834023B2
(en)
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
WO2008085506A1
(en)
*
|
2007-01-03 |
2008-07-17 |
Cortex Pharmaceuticals, Inc. |
3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
|
|
US8618074B2
(en)
|
2007-03-15 |
2013-12-31 |
Board Of Regents Of The University Of Texas System |
GPCR enhanced neuroprotection to treat brain injury
|
|
WO2009032116A1
(en)
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
2, 3-substituted indole derivatives for treating viral infections
|
|
KR20100067652A
(ko)
|
2007-08-29 |
2010-06-21 |
쉐링 코포레이션 |
치환된 인돌 유도체 및 이의 사용방법
|
|
KR20100065167A
(ko)
|
2007-08-29 |
2010-06-15 |
쉐링 코포레이션 |
바이러스 감염 치료용 2,3-치환된 아자인돌 유도체
|
|
WO2009039461A2
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
CA2700331A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
Co-administration of pimavanserin with other agents
|
|
CA2705587A1
(en)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
MX2010005356A
(es)
|
2007-11-16 |
2010-05-27 |
Schering Corp |
Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
|
|
US20110024198A1
(en)
|
2008-02-19 |
2011-02-03 |
Baker Hughes Incorporated |
Bearing systems containing diamond enhanced materials and downhole applications for same
|
|
WO2010042603A1
(en)
|
2008-10-08 |
2010-04-15 |
Cingulate Neuro Therapeutics, Llc |
Amyloid and depression
|
|
HRP20120992T1
(hr)
|
2008-11-20 |
2012-12-31 |
Merck Sharp & Dohme Corp. |
Aril metil benzokinazolinon kao pozitivni alosterni modulatori receptora m1
|
|
JP2012518640A
(ja)
|
2009-02-23 |
2012-08-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター
|
|
SG174220A1
(en)
|
2009-03-05 |
2011-10-28 |
Mithridion Inc |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
WO2010123716A1
(en)
|
2009-04-20 |
2010-10-28 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
|
|
ES2353093B1
(es)
|
2009-05-20 |
2012-01-03 |
Consejo Superior De Investigaciones Científicas (Csic) |
Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
|
|
US20110020423A1
(en)
|
2009-07-22 |
2011-01-27 |
Puretech Ventures |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
US10265311B2
(en)
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
BR112012003464B8
(pt)
|
2009-08-31 |
2021-05-25 |
Merck Sharp & Dohme |
compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
|
|
US8895580B2
(en)
|
2009-10-21 |
2014-11-25 |
Merck Sharp & Dohme Corp. |
Quinolinone-pyrazolone M1 receptor positive allosteric modulators
|
|
US8664387B2
(en)
|
2009-12-14 |
2014-03-04 |
Merck Sharp & Dohme Corp. |
Pyridoquinazolinone M1 receptor positive allosteric modulators
|
|
US8383638B2
(en)
|
2009-12-21 |
2013-02-26 |
Merck Sharp & Dohme |
Aminobenzoquinazolinone M1 receptor positive allosteric modulators
|
|
WO2011159553A1
(en)
|
2010-06-15 |
2011-12-22 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
|
|
EP2588104B1
(en)
|
2010-07-01 |
2014-12-10 |
Merck Sharp & Dohme Corp. |
Isoindolone m1 receptor positive allosteric modulators
|
|
WO2012047702A1
(en)
*
|
2010-10-04 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
|
|
WO2012149524A1
(en)
|
2011-04-29 |
2012-11-01 |
The University Of Toledo |
Muscarinic agonists as enhancers of working memory and cognitive flexibility
|
|
EP2709624B1
(en)
*
|
2011-05-17 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
|
|
WO2012170599A1
(en)
|
2011-06-10 |
2012-12-13 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
US9403802B2
(en)
|
2012-03-02 |
2016-08-02 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound and use therefor
|
|
US9914722B2
(en)
|
2012-03-23 |
2018-03-13 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
WO2014077401A1
(ja)
|
2012-11-19 |
2014-05-22 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
JP6075408B2
(ja)
|
2012-11-22 |
2017-02-08 |
株式会社デンソー |
物標検出装置
|
|
CA2886139A1
(en)
|
2012-12-27 |
2014-07-03 |
F. Hoffmann-La Roche Ag |
Comt inhibitors
|
|
WO2014117920A1
(en)
|
2013-02-04 |
2014-08-07 |
Merck Patent Gmbh |
Spiro-quinazolinone derivatives useful for the treatment of neurological diseases and conditions
|
|
US10738024B2
(en)
|
2013-05-06 |
2020-08-11 |
Indiana University Research And Technology Corporation |
Compounds for treatment of angiogenesis-mediated diseases
|
|
JP6063400B2
(ja)
|
2014-01-08 |
2017-01-18 |
株式会社日立ビルシステム |
エレベータの異常監視装置
|
|
AU2015250610B2
(en)
|
2014-04-23 |
2019-02-07 |
Takeda Pharmaceutical Company Limited |
Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
|
|
US10208046B2
(en)
|
2014-05-16 |
2019-02-19 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
EP3156397B1
(en)
|
2014-06-13 |
2019-08-07 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
TW201710255A
(zh)
*
|
2015-06-26 |
2017-03-16 |
武田藥品工業股份有限公司 |
雜環化合物
|
|
WO2017044693A1
(en)
|
2015-09-11 |
2017-03-16 |
Chase Pharmaceuticals Corporation |
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
US10548899B2
(en)
|
2015-10-20 |
2020-02-04 |
Takeda Pharmaceutical Company Limited |
Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
|
|
EP3428150B1
(en)
|
2016-03-11 |
2023-07-12 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
|
|
CN110337289A
(zh)
|
2016-12-29 |
2019-10-15 |
Rvx疗法有限公司 |
用于增强cns药物并减轻它们的副作用的方法和组合物
|